ClinicalTrials.gg
CompletedNCT02924376Updated Aug 14, 2025Results posted

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

A Phase 2 interventional study of Pemigatinib in Cholangiocarcinoma, sponsored by Incyte Corporation. Completed at 120 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pemigatinib in Cholangiocarcinoma — 6 open to participants now, 6 under way, none of them phase 3. pemigatinib · Cholangiocarcinoma.

Enrollment
3rd of 13
147 · median 34
Started
2017
the only one that year
Phase 2
8 of 13
4 open now
Registered
2nd of 13
by date
Lead sponsor
4 of 13
Incyte Corporation

Among the 13 studies testing pemigatinib in Cholangiocarcinoma, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 8 in phase 2, and was the 2nd registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

6 of the 13 studies testing pemigatinib in Cholangiocarcinoma are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pemigatinib

pemigatinib: first FDA approval 2020 (PEMAZYRE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pemigatinib in Cholangiocarcinoma, or all of them as a file.
02

Study summary

The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

03

Conditions studied

  • Cholangiocarcinoma

Keywords

  • Cholangiocarcinoma
  • fibroblast growth factor (FGF)
  • fibroblast growth factor receptor (FGFR)
  • FGF/FGFR alterations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed cholangiocarcinoma.
  • Radiographically measurable or evaluable disease per v1.1.
  • Tumor assessment for FGF/FGFR gene alteration status.
  • Documented disease progression after at least 1 line of prior systemic therapy.
  • (ECOG) performance status of 0 to 2.
  • ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of a selective FGFR inhibitor.
  • History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.
  • Current evidence of corneal or retinal disorder confirmed by ophthalmologic examination.
  • Use of any potent inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Cohort A Pemigatinib

    Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report

    Drug: Pemigatinib

  • Experimental
    Cohort B Pemigatinib

    Pemigatinibin subjects with other FGF/FGFR alterations

    Drug: Pemigatinib

  • Experimental
    Cohort C Pemigatinib

    Pemigatinib in subjects negative for FGF/FGFR alteration

    Drug: Pemigatinib

Interventions

  • Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy

    Also known as: INCB054828

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions

    ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.

    Time frame: up to 1527 days

Secondary outcomes

  1. ORR in Participants FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions

    ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.

    Time frame: up to 424 days

  2. ORR in All Participants With FGF/FGFR Alterations

    ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.

    Time frame: up to 1527 days

  3. ORR in Participants Negative for FGF/FGFR Alterations

    ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.

    Time frame: up to 143 days

  4. Progression-free Survival (PFS)

    PFS was defined as the length of time from the first dose of study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.

    Time frame: up to 50.17 months

  5. Duration of Response (DOR)

    DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) as assessed by an independent centralized radiological review committee to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

    Time frame: up to 47.11 months

  6. Disease Control Rate (DCR)

    DCR was defined as the proportion of participants with an overall response of CR, PR, or stable disease (SD), per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.

    Time frame: up to 1527 days

  7. Overall Survival

    Overall survival was defined as the length of time from the first dose of study drug (Day 1) until the date of death due to any cause.

    Time frame: up to 51.32 months

  8. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was defined as any adverse event either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.

    Time frame: up to 1584 days

  9. First-order Absorption Rate Constant (ka) of Pemigatinib

    First-order absorption rate constant is defined as the rate at which a drug enters into the system.

    Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose

  10. CL/F of Pemigatinib

    CL/F is defined as apparent oral clearance.

    Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose

  11. Vc/F of Pemigatinib

    Vc/F is defined as the apparent volume of distribution for the central compartment of pemigatinib.

    Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose

  12. Vp/F of Pemigatinib

    Vp/F is defined as the apparent volume of distribution for the tissue (peripheral) compartment.

    Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose

07

Results

Posted Feb 23, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
Started10820172
Completed0000
Not completed10820172
Withdrew: Progressive disease4010
Withdrew: Death7318152
Withdrew: Lost to follow-up3000
Withdrew: Study terminated by sponsor19000
Withdrew: Physician decision1000
Withdrew: Withdrawal by subject7210
Withdrew: Rolled over to another study1000

Outcome measures

PrimaryObjective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions

ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.

Time frame:
up to 1527 days
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions
percentage of participantsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions37.0 (27.94 to 46.86)———
SecondaryORR in Participants FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions

ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.

Time frame:
up to 424 days
Reported as:
Number · percentage of participants
ORR in Participants FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions
percentage of participantsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
ORR in Participants FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions—0.0 (0.0 to 16.84)——
SecondaryORR in All Participants With FGF/FGFR Alterations

ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.

Time frame:
up to 1527 days
Reported as:
Number · percentage of participants
ORR in All Participants With FGF/FGFR Alterations
percentage of participantsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOtherCohort A + Cohort B
ORR in All Participants With FGF/FGFR Alterations————31.3 (23.35 to 40.04)
SecondaryORR in Participants Negative for FGF/FGFR Alterations

ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.

Time frame:
up to 143 days
Reported as:
Number · percentage of participants
ORR in Participants Negative for FGF/FGFR Alterations
percentage of participantsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
ORR in Participants Negative for FGF/FGFR Alterations——0.0 (0.0 to 19.51)—
SecondaryProgression-free Survival (PFS)

PFS was defined as the length of time from the first dose of study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.

Time frame:
up to 50.17 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
Progression-free Survival (PFS)7.03 (6.08 to 10.48)2.10 (1.18 to 4.86)1.51 (1.38 to 1.84)—
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) as assessed by an independent centralized radiological review committee to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

Time frame:
up to 47.11 months
Reported as:
Median · months
Duration of Response (DOR)
monthsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
Duration of Response (DOR)9.13 (6.01 to 14.49)———
SecondaryDisease Control Rate (DCR)

DCR was defined as the proportion of participants with an overall response of CR, PR, or stable disease (SD), per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.

Time frame:
up to 1527 days
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
Disease Control Rate (DCR)82.4 (73.9 to 89.1)40.0 (19.1 to 63.9)17.6 (3.8 to 43.4)—
SecondaryOverall Survival

Overall survival was defined as the length of time from the first dose of study drug (Day 1) until the date of death due to any cause.

Time frame:
up to 51.32 months
Reported as:
Median · months
Overall Survival
monthsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
Overall Survival17.48 (14.36 to 22.93)6.70 (2.10 to 10.55)3.98 (1.97 to 4.60)—
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was defined as any adverse event either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.

Time frame:
up to 1584 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOther
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)10820172
SecondaryFirst-order Absorption Rate Constant (ka) of Pemigatinib

First-order absorption rate constant is defined as the rate at which a drug enters into the system.

Time frame:
Predose; 1-2 hours post-dose; 4-12 hours post-dose
Reported as:
Mean · 1/hour
First-order Absorption Rate Constant (ka) of Pemigatinib
1/hourAll Cohorts
First-order Absorption Rate Constant (ka) of Pemigatinib1.29 ± 0.827
SecondaryCL/F of Pemigatinib

CL/F is defined as apparent oral clearance.

Time frame:
Predose; 1-2 hours post-dose; 4-12 hours post-dose
Reported as:
Mean · Liters/hour
CL/F of Pemigatinib
Liters/hourAll Cohorts
CL/F of Pemigatinib12.2 ± 5.28
SecondaryVc/F of Pemigatinib

Vc/F is defined as the apparent volume of distribution for the central compartment of pemigatinib.

Time frame:
Predose; 1-2 hours post-dose; 4-12 hours post-dose
Reported as:
Mean · Liters
Vc/F of Pemigatinib
LitersAll Cohorts
Vc/F of Pemigatinib144 ± 55.7
SecondaryVp/F of Pemigatinib

Vp/F is defined as the apparent volume of distribution for the tissue (peripheral) compartment.

Time frame:
Predose; 1-2 hours post-dose; 4-12 hours post-dose
Reported as:
Mean · Liters
Vp/F of Pemigatinib
LitersAll Cohorts
Vp/F of Pemigatinib85.6 ± 30.5

Adverse events

Collected over up to 1584 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: FGFR2 Rearrangements or Fusions76/108 (70.4%)46/108 (42.6%)108/108 (100%)
Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions18/20 (90%)10/20 (50%)20/20 (100%)
Cohort C: Negative for FGF/FGFR Alterations15/17 (88.2%)12/17 (70.6%)17/17 (100%)
Other2/2 (100%)0/2 (0%)2/2 (100%)
Total111/147 (75.5%)68/147 (46.3%)147/147 (100%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOtherTotal
Abdominal painGastrointestinal disorders4/1081/202/170/27/147
Back painMusculoskeletal and connective tissue disorders0/1080/202/170/22/147
HyponatraemiaMetabolism and nutrition disorders1/1082/200/170/23/147
Pleural effusionRespiratory, thoracic and mediastinal disorders2/1082/201/170/25/147
Acute kidney injuryRenal and urinary disorders2/1080/201/170/23/147
AnaemiaBlood and lymphatic system disorders1/1080/201/170/22/147
Anaphylactic reactionImmune system disorders0/1080/201/170/21/147
BilomaHepatobiliary disorders0/1080/201/170/21/147
Blood creatinine increasedInvestigations1/1080/201/170/22/147
CholangitisHepatobiliary disorders5/1080/201/170/26/147
Most frequent other events
Showing 10 of 194
Most frequent other events
EventCohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOtherTotal
AlopeciaSkin and subcutaneous tissue disorders64/1084/203/172/273/147
Dry mouthGastrointestinal disorders42/1085/201/172/250/147
Dry skinSkin and subcutaneous tissue disorders30/1080/200/172/232/147
DysgeusiaNervous system disorders45/1083/203/172/253/147
HyperphosphataemiaMetabolism and nutrition disorders60/10813/2012/171/286/147
DiarrhoeaGastrointestinal disorders58/1085/206/171/270/147
FatigueGeneral disorders50/1085/209/170/264/147
Abdominal painGastrointestinal disorders22/1083/203/171/229/147
Activated partial thromboplastin time prolongedInvestigations3/1080/200/171/24/147
ConstipationGastrointestinal disorders46/1085/202/171/254/147

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOtherTotal
Mean55.2 ± 12.0061.9 ± 10.9965.6 ± 7.1241.0 ± 14.1457.1 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOtherTotal
Female66117185
Male42910162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOtherTotal
White799142104
Black or African American70108
Asian12110023
American-Indian/Alaska Native00101
Captured as "Other"40105
Missing60006
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: FGFR2 Rearrangements or FusionsCohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or FusionsCohort C: Negative for FGF/FGFR AlterationsOtherTotal
Hispanic or Latino20406
Not Hispanic or Latino8818132121
Not Reported1500015
Unknown10001
Captured as "Other"22004
08

Study locations

120 sites
  • Anchorage, Alaska, United States
  • Phoenix, Arizona, United States
  • Tempe, Arizona, United States
  • Tucson, Arizona, United States
  • Orange, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • New Haven, Connecticut, United States
  • Newark, Delaware, United States
  • Washington D.C., District of Columbia, United States
  • Gainesville, Florida, United States
  • Miami Beach, Florida, United States
  • Chicago, Illinois, United States
  • Evanston, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Sioux City, Iowa, United States
  • Westwood, Kansas, United States
  • Louisville, Kentucky, United States
  • Baltimore, Maryland, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Rochester, Minnesota, United States
  • Woodbury, Minnesota, United States
  • St Louis, Missouri, United States
  • Billings, Montana, United States
  • Omaha, Nebraska, United States
  • Morristown, New Jersey, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Charlotte, North Carolina, United States
  • Goldsboro, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Sioux Falls, South Dakota, United States
  • Arlington, Texas, United States
  • Dallas, Texas, United States
  • Grapevine, Texas, United States
  • San Antonio, Texas, United States
  • The Woodlands, Texas, United States
  • Tyler, Texas, United States
  • Waco, Texas, United States
  • Salt Lake City, Utah, United States
  • Fairfax, Virginia, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
  • Brussels, Belgium
  • Ghent, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Montpellier, Herault, France
  • Villejuif, Herault, France
  • Avignon, France
  • Clichy, France
  • Paris, France
  • Toulouse, France
  • Berlin, Germany
  • Bonn, Germany
  • Dresden, Germany
  • Hanover, Germany
  • Homburg, Germany
  • Leipzig, Germany
  • Mainz, Germany
  • Tübingen, Germany
  • Jerusalem, Israel
  • Petah Tikva, Israel
  • Ramat Gan, Israel
  • Tel Aviv, Israel
  • Bari, Castellana Grotte, Italy
  • San Giovanni Rotondo, Foggia, Italy
  • Bergamo, Italy
  • Bologna, Italy
  • Candiolo, Italy
  • Catania, Italy
  • Faenza, Italy
  • Lecce, Italy
  • Meldola, Italy
  • Milan, Italy
  • Naples, Italy
  • Rimini, Italy
  • Siena, Italy
  • Verona, Italy
  • Nagoya, Aichi-ken, Japan
  • Chiba, Chiba, Japan
  • Fukuoka, Fukuoka, Japan
  • Yokohama, Kanagawa, Japan
  • Kyoto, Kyoto, Japan
  • Osaka, Osaka, Japan
  • Osakasayama-shi, Osaka, Japan
  • Kitaadachi, Saitama, Japan
  • Sunto, Shizuoka, Japan
  • Kōtoku, Tokyo-To, Japan
  • Shinjuku-ku, Tokyo-To, Japan
  • Goyang-si, South Korea
  • Seongnam-si, South Korea
  • Seoul, South Korea
  • Pamplona, Navarre, Spain

Showing the first 100 of 120 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Patel TH, Marcus L, Horiba MN, Donoghue M, Chatterjee S, Mishra-Kalyani PS, Schuck RN, Li Y, Zhang X, Fourie Zirkelbach J, Charlab R, Liu J, Yang Y, Lemery SJ, Pazdur R, Theoret MR, Fashoyin-Aje LA. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement. Clin Cancer Res. 2023 Mar 1;29(5):838-842. doi: 10.1158/1078-0432.CCR-22-2036. PubMed 36206041 ↗
  • Bibeau K, Feliz L, Lihou CF, Ren H, Abou-Alfa GK. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. JCO Precis Oncol. 2022 Apr;6:e2100414. doi: 10.1200/PO.21.00414. PubMed 35544727 ↗
  • Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Feliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20. PubMed 32203698 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Feb 2022, 60 months.

Results were first posted in Feb 2023, 1 year after primary completion.

Of 173 phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2016
First posted
Oct 5, 2016
StartActual
Jan 16, 2017
Primary completionActual
Feb 1, 2022
CompletionActual
Feb 1, 2022
Results first posted
Feb 23, 2023
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02924376
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 5, 2016
Start date
Jan 16, 2017
Primary completion
Feb 1, 2022
Completion
Feb 1, 2022
Results posted
Feb 23, 2023
Last update
Aug 14, 2025

Study contacts

Luis Féliz Vinas, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion